Positron emission tomography imaging of cancer biology: Current status and future prospects

Seminars in Oncology

Volumn 38, Issue 1, 2011, Pages 70-86

  Chen, Kai ^a   Chen, Xiaoyuan ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID CETUXIMAB CU 64; 1,4,7,10 TETRAAZACYCLODODECANE N,N',N'',N''' TETRAACETIC ACID PANITUMUMAB CU 64; CETUXIMAB; COPPER 64; CYCLOPHOSPHAMIDE; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE CU 64; ENDOTHELIAL CELL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; FIBROBLAST GROWTH FACTOR; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GALACTO RGD PEPTIDE F 18; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOCORTIN 5; MATRIX METALLOPROTEINASE; PANITUMUMAB; PEGYLATED TETRAMERIC RGD PEPTIDE F 18; PIMONIDAZOLE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELL PROLIFERATION; DRUG TUMOR LEVEL; DRUG UPTAKE; GLIOMA; GLIOSARCOMA; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; NEOPLASM; ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; UTERINE CERVIX CARCINOMA;

APOPTOSIS; CELL HYPOXIA; CELL PROLIFERATION; HUMANS; MOLECULAR IMAGING; MOLECULAR PROBES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, SOMATOSTATIN;

EID: 79952162068     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.11.005     Document Type: Article

References (125)

1. 13N radiolabels for positron emission tomography Angew Chem Int Ed Engl 47 2008 8998 9033
2. 18F-fluorodeoxyglucose PET/CT in cancer imaging Clin Med 6 2006 240 244
3. G.J. Kelloff, J.M. Hoffman, and B. Johnson Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development Clin Cancer Res 11 2005 2785 2808 (Pubitemid 40525178)
4. E.M. Rohren, T.G. Turkington, and R.E. Coleman Clinical applications of PET in oncology Radiology 231 2004 305 332 (Pubitemid 38552885)
5. Y.P. Chen, and F. Chen Identifying targets for drug discovery using bioinformatics Expert Opin Ther Targets 12 2008 383 389 (Pubitemid 351546366)
6. E.W. Klee, J.A. Finlay, and C. McDonald Bioinformatics methods for prioritizing serum biomarker candidates Clin Chem 52 2006 2162 2164
7. D.R. Rhodes, and A.M. Chinnaiyan Bioinformatics strategies for translating genome-wide expression analyses into clinically useful cancer markers Ann N Y Acad Sci 1020 2004 32 40 (Pubitemid 38736922)
8. D.R. Rhodes, S. Kalyana-Sundaram, and V. Mahavisno Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles Neoplasia 9 2007 166 180
9. Y. Yang, S.J. Adelstein, and A.I. Kassis Target discovery from data mining approaches Drug Discov Today 14 2009 147 154
10. P. Carmeliet Angiogenesis in health and disease Nat Med 9 2003 653 660 (Pubitemid 36749213)
11. G. Bergers, and L.E. Benjamin Tumorigenesis and the angiogenic switch Nat Rev Cancer 3 2003 401 410 (Pubitemid 37328844)
12. L.M. Ellis, W. Liu, and S.A. Ahmad Overview of angiogenesis: biologic implications for antiangiogenic therapy Semin Oncol 28 2001 94 104 (Pubitemid 33065115)
13. M. Kuwano, J. Fukushi, and M. Okamoto Angiogenesis factors Intern Med 40 2001 565 572 (Pubitemid 32799384)
14. G.D. Yancopoulos, S. Davis, N.W. Gale, J.S. Rudge, S.J. Wiegand, and J. Holash Vascular-specific growth factors and blood vessel formation Nature 407 2000 242 248
15. P. Carmeliet Mechanisms of angiogenesis and arteriogenesis Nat Med 6 2000 389 395 (Pubitemid 30208155)
16. M. Nguyen Angiogenic factors as tumor markers Invest New Drugs 15 1997 29 37 (Pubitemid 27217749)
17. P. Carmeliet, and R.K. Jain Angiogenesis in cancer and other diseases Nature 407 2000 249 257
18. B.P. Eliceiri, and D.A. Cheresh The role of alphav integrins during angiogenesis Mol Med 4 1998 741 750
19. W. Cai, and X. Chen Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism Anticancer Agents Med Chem 6 2006 407 428 (Pubitemid 44377776)
20. H. Jin, and J. Varner Integrins: roles in cancer development and as treatment targets Br J Cancer 90 2004 561 565 (Pubitemid 38297190)
21. G.J. Mizejewski Role of integrins in cancer: survey of expression patterns Proc Soc Exp Biol Med 222 1999 124 138
22. E. Ruoslahti, and M.D. Pierschbacher New perspectives in cell adhesion: RGD and integrins Science 238 1987 491 497 (Pubitemid 17147032)
23. J.P. Xiong, T. Stehle, and R. Zhang Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand Science 296 2002 151 155 (Pubitemid 34280076)
24. M. Aumailley, M. Gurrath, G. Muller, J. Calvete, R. Timpl, and H. Kessler Arg-Gly-Asp constrained within cyclic pentapeptides Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1 FEBS Lett 291 1991 50 54
25. R. Haubner, D. Finsinger, and H. Kessler Stereoisomeric peptide libraries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy Angew Chem Int Ed Engl 36 1997 1374 1389
26. R. Haubner, H.J. Wester, and U. Reuning Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting J Nucl Med 40 1999 1061 1071 (Pubitemid 29269229)
27. 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression J Nucl Med 45 2004 1776 1783 (Pubitemid 47618490)
28. J.M. Harris, N.E. Martin, and M. Modi Pegylation: a novel process for modifying pharmacokinetics Clin Pharmacokinet 40 2001 539 551 (Pubitemid 32738660)
29. R. Haubner Alphavbeta3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 33 Suppl 1 2006 54 63
30. R. Haubner, H.J. Wester, and F. Burkhart Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics J Nucl Med 42 2001 326 336 (Pubitemid 32150525)
31. 18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates Bioconjug Chem 15 2004 61 69 (Pubitemid 38165981)
32. 18F]Galacto-RGD PLoS Med 2 2005 e70
33. 18F-labeled RGD-containing glycopeptide and positron emission tomography Cancer Res 61 2001 1781 1785 (Pubitemid 32691983)
34. 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression J Nucl Med 47 2006 763 769 (Pubitemid 46768438)
35. 18F-galacto-RGD in cancer patients J Nucl Med 46 2005 1333 1341 (Pubitemid 43733484)
36. 18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck Clin Cancer Res 13 2007 6610 6616 (Pubitemid 350206795)
37. 18F-FDG J Nucl Med 49 2008 22 29
38. R. Haubner, and C. Decristoforo Radiolabelled RGD peptides and peptidomimetics for tumour targeting Front Biosci 14 2009 872 886
39. 18F-labeled PEGylated RGD peptide Eur J Nucl Med Mol Imaging 31 2004 1081 1089 (Pubitemid 39050174)
40. D. Boturyn, J.L. Coll, E. Garanger, M.C. Favrot, and P. Dumy Template assembled cyclopeptides as multimeric system for integrin targeting and endocytosis J Am Chem Soc 126 2004 5730 5739 (Pubitemid 38621412)
41. 64Cu-labeled dimeric RGD peptides Mol Imaging Biol 6 2004 350 359 (Pubitemid 39243068)
42. 64Cu-labeled RGD peptide Bioconjug Chem 15 2004 41 49 (Pubitemid 38165979)
43. 18F-labeled dimeric RGD peptide Mol Imaging 3 2004 96 104
44. 111In-labeled RGD peptide Nucl Med Biol 34 2007 29 35 (Pubitemid 46038156)
45. 18F-FPRGD4) J Nucl Med 48 2007 1536 1544 (Pubitemid 47397404)
46. 18F-FRGD2 J Nucl Med 47 2006 113 121 (Pubitemid 46768520)
47. A. Almutairi, R. Rossin, and M. Shokeen Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis Proc Natl Acad Sci U S A 106 2009 685 690
48. Z. Liu, W. Cai, and L. He In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice Nat Nanotechnol 2 2007 47 52 (Pubitemid 46210038)
49. A.R. Broumas, R.E. Pollard, S.H. Bloch, E.R. Wisner, S. Griffey, and K.W. Ferrara Contrast-enhanced computed tomography and ultrasound for the evaluation of tumor blood flow Invest Radiol 40 2005 134 147 (Pubitemid 40289440)
50. N. Ferrara VEGF and the quest for tumour angiogenesis factors Nat Rev Cancer 2 2002 795 803 (Pubitemid 37328914)
51. D.J. Hicklin, and L.M. Ellis Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 2005 1011 1027 (Pubitemid 46202320)
52. W. Cai, J. Rao, S.S. Gambhir, and X. Chen How molecular imaging is speeding up antiangiogenic drug development Mol Cancer Ther 5 2006 2624 2633 (Pubitemid 44848989)
53. K. Chen, W. Cai, Z.B. Li, H. Wang, and X. Chen Quantitative PET imaging of VEGF receptor expression Mol Imaging Biol 11 2009 15 22
54. A.R. Hsu, W. Cai, and A. Veeravagu Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel J Nucl Med 48 2007 445 454 (Pubitemid 47604931)
55. M.V. Backer, Z. Levashova, and V. Patel Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes Nat Med 13 2007 504 509 (Pubitemid 46559824)
56. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 2004 581 611 (Pubitemid 39099316)
57. H. Wang, W. Cai, and K. Chen A new PET tracer specific for vascular endothelial growth factor receptor 2 Eur J Nucl Med Mol Imaging 34 2007 2001 2010 (Pubitemid 350212131)
58. P. Vaupel, and L. Harrison Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response Oncologist 9 Suppl 5 2004 4 9 (Pubitemid 39658340)
59. P. Vaupel, and A. Mayer Hypoxia in cancer: significance and impact on clinical outcome Cancer Metastasis Rev 26 2007 225 239 (Pubitemid 47101660)
60. M. Hockel, and P. Vaupel Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects J Natl Cancer Inst 93 2001 266 276 (Pubitemid 32219813)
61. A.W. Fyles, M. Milosevic, and R. Wong Oxygenation predicts radiation response and survival in patients with cervix cancer Radiother Oncol 48 1998 149 156 (Pubitemid 28423786)
62. M. Nordsmark, S.M. Bentzen, and V. Rudat Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy An international multi-center study Radiother Oncol 77 2005 18 24 (Pubitemid 41503384)
63. D.M. Brizel, S.P. Scully, and J.M. Harrelson Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma Cancer Res 56 1996 941 943 (Pubitemid 26065381)
64. J.D. Chapman Hypoxic sensitizersimplications for radiation therapy N Engl J Med 301 1979 1429 1432
65. 18F-fluoromisonidazole Semin Nucl Med 37 2007 451 461 (Pubitemid 47498258)
66. K.A. Krohn, J.M. Link, and R.P. Mason Molecular imaging of hypoxia J Nucl Med 49 Suppl 2 2008 129S 148S (Pubitemid 351948041)
67. G. Mees, R. Dierckx, C. Vangestel, and C. Van de Wiele Molecular imaging of hypoxia with radiolabelled agents Eur J Nucl Med Mol Imaging 36 2009 1674 1686
68. J.S. Rasey, J.J. Casciari, P.D. Hofstrand, M. Muzi, M.M. Graham, and L.K. Chin Determining hypoxic fraction in a rat glioma by uptake of radiolabeled fluoromisonidazole Radiat Res 153 2000 84 92 (Pubitemid 30117087)
69. L. Dubois, W. Landuyt, K. Haustermans, P. Dupont, G. Bormans, and P. Vermaelen Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry Br J Cancer 91 2004 1947 1954 (Pubitemid 40065524)
70. 2- polarography in metastatic head and neck cancer Eur J Nucl Med Mol Imaging 33 2006 1426 1431 (Pubitemid 44885408)
71. 18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 7 2007 113
72. J.G. Rajendran, D.C. Wilson, and E.U. Conrad [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression Eur J Nucl Med Mol Imaging 30 2003 695 704 (Pubitemid 36612952)
73. 18F-FDG PET J Nucl Med 47 2006 1921 1926 (Pubitemid 47544979)
74. 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies J Nucl Med 47 2006 410 418 (Pubitemid 46768482)
75. J.G. Rajendran, D.L. Schwartz, and J. O'Sullivan Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer Clin Cancer Res 12 2006 5435 5441 (Pubitemid 44497258)
76. 18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study BMC Cancer 6 2006 51
77. 18F-fluoroazomycin arabinoside J Nucl Med 46 2005 106 113 (Pubitemid 43086004)
78. 18F]FAZAfirst small animal PET results J Pharm Pharm Sci 10 2007 203 211
79. A.L. Grosu, M. Souvatzoglou, and B. Roper Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer Int J Radiat Oncol Biol Phys 69 2007 541 551 (Pubitemid 47380112)
80. 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) J Nucl Med 47 2006 989 998 (Pubitemid 46939952)
81. C.S. Dence, D.E. Ponde, M.J. Welch, and J.S. Lewis Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer Nucl Med Biol 35 2008 713 720
82. 60Cu-ATSM in cancer of the uterine cervix J Nucl Med 49 2008 1177 1182 (Pubitemid 351948028)
83. F.G. Blankenberg In vivo imaging of apoptosis Cancer Biol Ther 7 2008 1525 1532
84. M.O. Hengartner The biochemistry of apoptosis Nature 407 2000 770 776
85. F.G. Blankenberg Recent advances in the imaging of programmed cell death Curr Pharm Des 10 2004 1457 1467 (Pubitemid 38559760)
86. G. Koopman, C.P. Reutelingsperger, G.A. Kuijten, R.M. Keehnen, S.T. Pals, and M.H. van Oers Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis Blood 84 1994 1415 1420 (Pubitemid 24273007)
87. H.H. Boersma, B.L. Kietselaer, and L.M. Stolk Past, present, and future of annexin A5: from protein discovery to clinical applications J Nucl Med 46 2005 2035 2050 (Pubitemid 46657451)
88. M.F. Corsten, L. Hofstra, J. Narula, and C.P. Reutelingsperger Counting heads in the war against cancer: defining the role of annexin A5 imaging in cancer treatment and surveillance Cancer Res 66 2006 1255 1260 (Pubitemid 43259900)
89. C.M. Lahorte, J.L. Vanderheyden, N. Steinmetz, C. Van de Wiele, R.A. Dierckx, and G. Slegers Apoptosis-detecting radioligands: current state of the art and future perspectives Eur J Nucl Med Mol Imaging 31 2004 887 919 (Pubitemid 38765126)
90. 18F-labelled annexin V: a PET tracer for apoptosis imaging Eur J Nucl Med Mol Imaging 31 2004 469 474 (Pubitemid 38461560)
91. X. Li, J.M. Link, and S. Stekhova Site-specific labeling of annexin V with F-18 for apoptosis imaging Bioconjug Chem 19 2008 1684 1688
92. 18F]-labeled isatin sulfonamide Proc Natl Acad Sci U S A 106 2009 16375 16380
93. P. Wells, R.N. Gunn, and M. Alison Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies Cancer Res 62 2002 5698 5702 (Pubitemid 35204724)
94. A.F. Shields Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology Mol Imaging Biol 8 2006 141 150 (Pubitemid 44193390)
95. A.F. Shields, J.R. Grierson, and B.M. Dohmen Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat Med 4 1998 1334 1336 (Pubitemid 28512118)
96. 18F]fluorothymidine positron emission tomography Cancer Res 66 2006 7621 7629 (Pubitemid 44289219)
97. F. McLaughlin, and N.B. La Thangue Histone deacetylase inhibitors open new doors in cancer therapy Biochem Pharmacol 68 2004 1139 1144 (Pubitemid 39094279)
98. B.S. Pio, C.K. Park, and R. Pietras Usefulness of 3′-[F-18]fluoro- 3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy Mol Imaging Biol 8 2006 36 42 (Pubitemid 44201576)
99. 18F]fluorothymidine positron emission tomography Eur J Nucl Med Mol Imaging 34 2007 1339 1347 (Pubitemid 47312585)
100. L.M. Kenny, D.M. Vigushin, and A. Al-Nahhas Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods Cancer Res 65 2005 10104 10112 (Pubitemid 41541493)
101. 11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET Nucl Med Biol 22 1995 783 789
102. J.R. Bading, A.H. Shahinian, and A. Vail Pharmacokinetics of the thymidine analog 2′-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (FMAU) in tumor-bearing rats Nucl Med Biol 31 2004 407 418 (Pubitemid 38490740)
103. H. Sun, T.J. Mangner, J.M. Collins, O. Muzik, K. Douglas, and A.F. Shields Imaging DNA synthesis in vivo with 18F-FMAU and PET J Nucl Med 46 2005 292 296 (Pubitemid 43073439)
104. P.S. Conti, J.R. Bading, and P.P. Mouton In vivo measurement of cell proliferation in canine brain tumor using C-11-labeled FMAU and PET Nucl Med Biol 35 2008 131 141 (Pubitemid 350298247)
105. 18F]FMAU and positron emission tomography in patients with cancer Eur J Nucl Med Mol Imaging 32 2005 15 22 (Pubitemid 40142774)
106. A.K. Buck, M. Bommer, and S. Stilgenbauer Molecular imaging of proliferation in malignant lymphoma Cancer Res 66 2006 11055 11061 (Pubitemid 44877006)
107. 18F-fluorothymidine in patients with gliomas J Nucl Med 47 2006 1612 1621 (Pubitemid 47545026)
108. D.S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183 232
109. K.E. Matheny, C.E. Barbieri, J.C. Sniezek, C.L. Arteaga, and J.A. Pietenpol Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells Laryngoscope 113 2003 936 939 (Pubitemid 36676585)
110. N.E. Hynes, and H.A. Lane ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 2005 341 354 (Pubitemid 40637826)
111. J.J. Laskin, and A.B. Sandler Epidermal growth factor receptor: a promising target in solid tumours Cancer Treat Rev 30 2004 1 17 (Pubitemid 38240085)
112. Z. Fan, H. Masui, I. Altas, and J. Mendelsohn Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies Cancer Res 53 1993 4322 4328 (Pubitemid 24146785)
113. 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody Eur J Nucl Med Mol Imaging 34 2007 850 858 (Pubitemid 46798960)
114. G. Niu, Z. Li, J. Xie, Q.T. Le, and X. Chen PET of EGFR antibody distribution in head and neck squamous cell carcinoma models J Nucl Med 50 2009 1116 1123
115. I. Velikyan, A.L. Sundberg, and O. Lindhe Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors J Nucl Med 46 2005 1881 1888 (Pubitemid 46196651)
116. 18F-FDG PET J Nucl Med 47 2006 793 796 (Pubitemid 46768442)
117. L. Bodei, G. Paganelli, and G. Mariani Receptor radionuclide therapy of tumors: a road from basic research to clinical applications J Nucl Med 47 2006 375 377 (Pubitemid 46768477)
118. J.C. Reubi, and B. Waser Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting Eur J Nucl Med Mol Imaging 30 2003 781 793 (Pubitemid 36612963)
119. C. Scarpignato, and I. Pelosini Somatostatin analogs for cancer treatment and diagnosis: an overview Chemotherapy 47 Suppl 2 2001 1 29
120. F. Forrer, R. Valkema, D.J. Kwekkeboom, M. de Jong, and E.P. Krenning Neuroendocrine tumors Peptide receptor radionuclide therapy Best Pract Res Clin Endocrinol Metab 21 2007 111 129 (Pubitemid 46421906)
121. 64Cu-TETA- octreotide as a PET imaging agent for patients with neuroendocrine tumors J Nucl Med 42 2001 213 221 (Pubitemid 32150511)
122. 68Ga-DOTA-Tyr3- octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT J Nucl Med 48 2007 508 518 (Pubitemid 47571404)
123. T.F. Massoud, and S.S. Gambhir Molecular imaging in living subjects: seeing fundamental biological processes in a new light Genes Dev 17 2003 545 580 (Pubitemid 36307540)
124. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging J Nucl Med 49 2008 453 461 (Pubitemid 351355212)
125. M. Rodriguez-Porcel, W. Cai, and O. Gheysens Imaging of VEGF receptor in a rat myocardial infarction model using PET J Nucl Med 49 2008 667 673 (Pubitemid 351520616)